Literature DB >> 18179577

Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience.

C E Neunert1, K L Miller, J M Journeycake, G R Buchanan.   

Abstract

Elective surgical procedures involving central venous access devices (CVADs) in patients with haemophilia are often necessary for adequate factor delivery but there are few data regarding haemostatic coverage and acute complication rates accompanying these procedures. To describe experience with CVAD insertion, revision and removal in young haemophilia patients at our institution and in the literature and to assess acute complications following CVAD procedures. PubMed, Medline and Cochrane databases were searched for articles, which included a description of factor coverage during CVAD procedures. A retrospective review of our comprehensive haemophilia database identified patients undergoing CVAD placement, revision and removal between January 1993 and August 2005. Manual and electronic searches of the published literature yielded 14 articles, which met inclusion criteria. Peri-operative factor administration varied greatly among the reports. Mean acute infection and haematoma rates were 8% and 12.5% respectively. A retrospective review identified 49 CVAD placements, revisions, or removals meeting inclusion criteria. Most patients received outpatient bolus factor replacement to achieve a level of 100% preoperatively, immediately postoperatively and on postoperative days 1, 2, 3, 5 and 7. Thirty-six procedures were performed without hospitalization. Ten patients developed 11 (22%) minor haematomas postoperatively. Major haemorrhage, acute infection, or pneumothorax was not encountered. Few published data exist regarding haemostatic coverage and complications following CVAD procedures. Our institutional experience using a consistent management approach was favourable. Further studies are required to define optimal haemostatic coverage during minor surgical procedures in haemophilia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18179577     DOI: 10.1111/j.1365-2516.2007.01605.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  Deep venous thrombosis screening in patients with inherited bleeding disorders and central venous catheters.

Authors:  C R Cost; J M Journeycake
Journal:  Haemophilia       Date:  2011-03-24       Impact factor: 4.287

2.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

3.  Revisiting hemophilia management in acute medicine.

Authors:  Sandeep Sahu; Indu Lata; Surendra Singh; Mukesh Kumar
Journal:  J Emerg Trauma Shock       Date:  2011-04

4.  Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients.

Authors:  Tim Preijers; Ri Liesner; Hendrika C A M Hazendonk; Pratima Chowdary; Mariëtte H E Driessens; Dan P Hart; Britta A P Laros-van Gorkom; Felix J M van der Meer; Karina Meijer; Karin Fijnvandraat; Frank W G Leebeek; Ron A A Mathôt; Marjon H Cnossen
Journal:  Br J Clin Pharmacol       Date:  2021-05-04       Impact factor: 4.335

5.  Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia.

Authors:  Julia Lischka; Klaus Arbeiter; Charlotte de Gier; Andrea Willfort-Ehringer; Nina-Katharina Walleczek; Renata Gellai; Michael Boehm; Albert Wiegman; Susanne Greber-Platzer
Journal:  BMC Pediatr       Date:  2022-03-12       Impact factor: 2.567

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.